The clinical-stage biotech might have a successful drug on its hands, if a relatively early-stage clinical trial is any indication. Its REC-4881 did very well in the testing. 10 stocks we like better ...
Before market open, Recursion divulged that its REC-4881 demonstrated notable efficacy in a phase 1b/2 trial. The drug, which treats a disorder called familial adenomatous polyposis (FAP) in which ...
Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...
Abstract: This paper introduces an innovative recursive methodology for ultra-fast load flow analysis. The approach is based on the Holomorphic Embedding Load Flow Method (HELM) and employs the Total ...
Abstract: Tackling the challenge of open-switch (OS) fault diagnostics in grid-tied three-level neutral point clamped (NPC) inverters with parameter uncertainty, this paper introduces a fault ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback